The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease

Endocrine Pathology

Volumn 16, Issue 1, 2005, Pages 63-66

  Erkiliç, Suna ^a,b   Koçer, N Emrah ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Fevzi Cakmak Bulv   (Turkey)

Author keywords

Cytokeratin 19; Graves' disease; Papillary carcinoma; Thyroid

Indexed keywords

CYTOKERATIN 19;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GRAVES DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; STAINING; THYROID ADENOMA; THYROID PAPILLARY CARCINOMA;

EID: 24644456920     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/ep:16:1:063     Document Type: Article

References (14)

1. Rosai J. Thyroid gland. In Rosai J, ed. Rosai and Ackerman's surgical pathology, 9th ed., St. Louis, MO: Mosby, 2004; 515-594.
2. Daou R. Hyperthyroidism and cancer of the thyroid. Chirurgie. 123(6):604-608, 1998.
3. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland. Atlas of thyroid pathology, 3rd series, fascicle 5. Washington DC: Armed Forces Institute of Pathology, 1992.
4. Erkilic S, Aydin A, Kocer NE. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Path 13(3):207-211, 2002.
5. Gabriele R, Letizia C, Borghese M, et al. Thyroid cancer in patients with hyperthyroidism. Horm Res 60(2):79-83, 2003.
6. Miettinen M, Fetsch JF. Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors: implications in tumor diagnosis. Hum Pathol 31:1062-1067, 2000.
7. Judkins AR, Roberts SA, Livolsi VA. Utility of immunohistochemistry in the evaluation of necrotic thyroid tumors. Hum Pathol 30:1373-1376, 1999.
8. Schelfout LJ, Van Muijen GN, Fleuren GJ. Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma. Am J Clin Pathol 92:654-658, 1989.
9. Bennett WP, Bhan AK, Vickery AL Jr. Keratin expression as a diagnostic adjunct in thyroid tumors with papillary architecture. Lab Invest 58:9A, 1988.
10. Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma. Am J Clin Pathol 116:696-702, 2001.
11. Miettinen M, Fransilla KO. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma. Hum Pathol 31(9):1139-1145, 2000.
12. Schroder S, Wodzynski A, Padberg B. Cytokeratin expression of benign and malignant epithelial thyroid gland tumors: an immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies. Pathologe 17(6):425-432, 1996.
13. Baloch ZW, Abraham S, Roberts S, LiVolsi VA. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and diagnostic utility. Hum Pathol 30:1166-1171, 1999.
14. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 14(1):55-60, 2003.